Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Ku Mingo
   2. Issuer Name and Ticker or Trading Symbol
SOLTA MEDICAL INC [SLTM] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Vice President of Global Sales
(Last)
(First)
(Middle)
C/O SOLTA MEDICAL, INC., 25881 INDUSTRIAL BLVD.		 3. Date of Earliest Transaction (Month/Day/Year)
01/23/2014
(Street)

HAYWARD, CA 94545		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/23/2014   D   41,378 (1) D $ 2.92 0 D  
Common Stock 01/23/2014   M   5,963 (2) A (2) 5,963 D  
Common Stock 01/23/2014   D   5,963 D $ 2.92 0 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Restricted Stock Unit (2) 01/23/2014   M     5,963   (2) 02/04/2023 Common Stock 5,963 (2) 0 D  
Employee Stock Option (Right to Buy) $ 1.37 01/23/2014   D     20,000   (3) 12/31/2018 Common Stock 20,000 $ 1.55 0 D  
Employee Stock Option (Right to Buy) $ 1.51 01/23/2014   D     2,000   (3) 07/31/2019 Common Stock 2,000 $ 1.41 0 D  
Employee Stock Option (Right to Buy) $ 2.75 01/23/2014   D     3,000   (3) 01/31/2021 Common Stock 3,000 $ 0.17 0 D  
Employee Stock Option (Right to Buy) $ 2.77 01/23/2014   D     50,000   (3) 12/11/2022 Common Stock 50,000 $ 0.15 0 D  
Employee Stock Option (Right to Buy) $ 2.56 01/23/2014   D     2,500   (3) 01/31/2023 Common Stock 2,500 $ 0.36 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Ku Mingo
C/O SOLTA MEDICAL, INC.
25881 INDUSTRIAL BLVD.
HAYWARD, CA 94545		       Vice President of Global Sales  

Signatures

 /s/ Mingo Ku   01/27/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Disposed of pursuant to the merger of the Issuer with Valeant Pharmaceuticals International, a Delaware corporation (the "Merger"), at the merger consideration of $2.92 per share (the "Merger Consideration"). Includes 28,166 shares deemed acquired pursuant to the grant of restricted stock units ("RSU s") on various dates. The vesting of the RSU's was accelerated in connection with the Merger.
(2) Each performance right represented a contingent right to receive a share of Issuer common stock based on the Issuer's stock price performance. In connection with the Merger, the vesting (thus, the settlement) of the performance right was accelerated.
(3) This option, which had become fully vested and exercisable, was cancelled at the closing of the Merger in exchange for a cash payment equal to the product of (a) the number of shares underlying this option and (b) the difference between the Merger Consideration and the exercise price per share of this option.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.